| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fc34172558459d5b4c88ed5012dff32 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-65 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-655
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1754
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-64 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-655
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 |
| filingDate |
2019-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_970bb18120ae142be2e4dbe7aa38334a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7af49ad975fa2219ee40463daf8fc64e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac480a5e4e24384b1902025c621d4816
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8eab5c33280ddd0b4edaee608e4d077e |
| publicationDate |
2021-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11192932-B2 |
| titleOfInvention |
Heparin-binding domain of IGFBP-2 in the treatment of metabolic disorders |
| abstract |
The present technology generally relates to compounds, in particular peptides comprising the heparin-binding domain (HBD) of insulin-like growth factor binding protein-2 (IGFBP-2) for the modulation of metabolic disorders. The present technology also generally relates to uses of such compounds in methods for preventing and/or treating metabolic disorders and in compositions and formulations for such uses. |
| priorityDate |
2018-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |